BACKGROUND: The @entity3003 -based chemotherapeutic regimen M-CAVI ( @entity1499 , @entity3003 , and @entity5713 ) is active against @entity150 and can be administered to @entity1 who are ineligible to receive @entity900 or @entity632 . The authors designed a randomized study to evaluate whether M-CAVI offers a therapeutic advantage over the @entity900 -based regimen M-VAC ( @entity1499 , @entity5713 , @entity632 , and @entity900 ) in the treatment of @entity1 with surgically incurable advanced @entity150 . METHODS: @entity1 with surgically incurable advanced @entity150 were enrolled on a randomized trial comparing M-CAVI, which consists of @entity3003 (300 mg/m2 on Day 2, adjusted using Calvert's formula for an area under the curve of 5), @entity1499 (30 mg/m2 on Days 1, 15, and 22), and @entity5713 (3 mg/m2 on Days 2, 15, and 22) administered every 28 days, versus standard M-VAC. The eligibility criteria included histologically proven @entity150 , surgically incurable disease, and no prior chemotherapy. @entity1 were treated until disease progression or unacceptable @entity137 occurred. RESULTS: From January 1989 to January 1994, 47 assessable @entity1 were included. Seventeen @entity1 had @entity1600 and 30 had distant metastatic disease. Twenty-three @entity1 were randomized to receive M-CAVI and 24 to receive M-VAC. @entity1 characteristics in the two groups were similar. Overall response rates were 39% (95% confidence interval [CI], 20-62%) for M-CAVI and 52% (95% CI, 30-73%) for M-VAC (P = 0.3), with 3 complete responses observed among @entity1 treated with M-VAC and none among those in the M-CAVI group. M-VAC was associated with more @entity344 , @entity3136 , @entity1665 , and Grade 4 @entity1398 than M-CAVI. One @entity137 -related @entity204 occurred in the M-VAC group. There was a statistically significant difference in median disease-related survival time favoring M-VAC (16 months; range, 6 to 22+) versus M-CAVI (9 months; range, 6 to 14+) (P = 0.03). CONCLUSIONS: M-CAVI is less toxic but less active than M-VAC in the treatment of @entity1 with advanced @entity150 . @entity3003 -based regimens in which @entity3003 is administered at the dose range used in the current study should be reserved for @entity1 who cannot tolerate @entity900 treatment. Further research is required to assess the impact of high dose @entity3003 in the treatment of this disease.

XXXX -based versus @entity900 -based chemotherapy in the treatment of surgically incurable advanced @entity150 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'Patient'] @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin'] @entity1665 :: ('MESH:D000505', 'Disease') :: ['alopecia'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity3136 :: ('MESH:D013280', 'Disease') :: ['stomatitis'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['Carboplatin', 'carboplatin'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1600 :: ('MESH:D014388', 'Disease') :: ['lymph node disease'] @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal toxicity'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder carcinoma'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity5713 :: ('MESH:D014747', 'Chemical') :: ['vinblastine']
@entity3003 :: (MESH:D016190,Chemical) :: ['Carboplatin']
